{"product_id":"ultragenyx-five-forces-analysis","title":"Ultragenyx  Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cpultragenyx faces high competitive intensity driven by biotech rivals and pricing pressure from payers while specialized suppliers regulatory hurdles shape its development costs time-to-market.\u003e\n\u003cpthis brief snapshot only scratches the surface. unlock full porter five forces analysis to explore ultragenyx competitive dynamics market pressures and strategic advantages in detail.\u003e\n\u003c\/pthis\u003e\u003c\/pultragenyx\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized CMO Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx depends on a handful of specialized CMOs for complex biologics and gene therapies; in 2024 roughly 70% of its advanced manufacturing capacity came from three external partners, raising supply concentration risk.\u003c\/p\u003e\n\u003cp\u003eThese CMOs hold rare technical expertise and facilities—viral vector suites and GMP gene-editing lines—hard to replicate; switching costs and lead times often exceed 12–18 months, giving suppliers pricing leverage.\u003c\/p\u003e\n\u003cp\u003eAs a result, suppliers can push higher contract prices and stricter terms; Ultragenyx reported manufacturing COGS up ~14% in FY2024, reflecting rising CMO rates and capacity premiums.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Raw Material Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of Ultragenyx rare-disease therapies depends on niche inputs—specialized cell lines and adeno-associated viral vectors—sourced from a handful of GMP-certified vendors; industry data show fewer than 10 global suppliers for key viral vectors as of 2025, so a single supplier disruption can delay batches by months and risk revenue loss (Ultragenyx 2024 sales $620m), giving suppliers strong bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSwitching suppliers in biotech forces FDA\/EMA re-validation, stability and GMP retesting that can take 9–18 months and cost $1–5M per supplier change; for Ultragenyx (market cap ~$4.2B in Dec 2025) this creates supplier lock-in.\u003c\/p\u003e\n\u003cp\u003eHigh time and capital barriers raise exit costs, so current suppliers can sustain 5–20% premium pricing, squeezing Ultragenyx margins on orphan-drug manufacture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers with patents on delivery mechanisms or proprietary cell lines give Ultragenyx little sourcing flexibility, raising supplier bargaining power in R\u0026amp;D and manufacturing. In 2024 Ultragenyx reported R\u0026amp;D spend of $602m, so a 10–20% price or access premium from IP-holder suppliers could materially raise program costs. Long-term renewals favor suppliers when switching requires licensing or tech transfer that adds 12–24 months and multi-million-dollar fees.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary patents limit substitutes\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D $602m (2024) increases exposure\u003c\/li\u003e\n\u003cli\u003eSwitching adds 12–24 months, multimillion fees\u003c\/li\u003e\n\u003cli\u003eSuppliers gain leverage in renewals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Stringency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers must meet Current Good Manufacturing Practices (cGMP), and only a few global CDMOs maintain consistent audit-ready status, concentrating capability among top providers.\u003c\/p\u003e\n\u003cp\u003eWith over 60% of advanced biologics outsourced to top-tier CDMOs in 2024, Ultragenyx competes directly with larger biotechs for limited compliant capacity, raising procurement costs and timeline risk.\u003c\/p\u003e\n\u003cp\u003eThis supply scarcity shifts bargaining power to compliant service providers, who can demand premium pricing and priority scheduling.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew audit-ready cGMP CDMOs worldwide\u003c\/li\u003e\n\u003cli\u003e60%+ advanced biologics outsourced (2024)\u003c\/li\u003e\n\u003cli\u003eHigher prices, longer lead times for compliant slots\u003c\/li\u003e\n\u003cli\u003eIncreased supplier leverage over Ultragenyx\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier oligopoly fuels 5–20% premiums: top-3 CMOs = 70%, high switch costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: three CMOs supplied ~70% of advanced capacity in 2024, fewer than 10 global AAV\/vector vendors in 2025, Ultragenyx COGS +14% FY2024, R\u0026amp;D $602m (2024); switching costs 9–24 months and $1–5M+ per change, enabling 5–20% price premiums.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-3 CMO share (2024)\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal AAV suppliers (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS change (FY2024)\u003c\/td\u003e\n\u003ctd\u003e+14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$602m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitch cost\u003c\/td\u003e\n\u003ctd\u003e9–24 months, $1–5M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier premium\u003c\/td\u003e\n\u003ctd\u003e5–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces for Ultragenyx uncovering competitive drivers, supplier and buyer power, substitution risks, and entry barriers, with strategic commentary on disruptive threats to its rare-disease biopharma position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, one-sheet Porter's Five Forces for Ultragenyx—ready to drop into decks to quickly assess bargaining power, competitive rivalry, and regulatory risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Payer Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrimary customers for Ultragenyx (biotech focused on rare diseases) are government payers and private insurers, not patients; US Medicare\/Medicaid and top insurers can demand large rebates or deny coverage—Medicaid rebates averaged ~23.1% in 2024 and specialty drug formulary exclusions rose 12% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmacy Benefit Managers (PBMs) set formularies and use tiering and prior authorization to control patient access, forcing Ultragenyx to grant steep rebates; in 2024 PBM-negotiated rebates averaged ~40% for specialty biologics, pressuring net price realization. PBMs can channel volume—up to 60% of specialty prescriptions pass through the top three PBMs (CVS Caremark, Express Scripts, Optum) in the US—giving them leverage to demand discounts or preferred placement. That leverage raises Ultragenyx’s commercial spend on rebates and can delay uptake by shifting patients away from its therapies through utilization management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity of Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic health systems in Europe and other markets use cost-effectiveness thresholds (e.g., £20,000–£30,000\/QALY in England) to judge coverage, letting single-payer buyers demand steep discounts for ultra-rare, high-cost therapies. Ultragenyx’s average list price per patient often exceeds $500,000, so national payers leverage volume and budget impact to push net prices down—reports show discounts of 30–60% for orphan drugs in some countries. This collective bargaining compresses Ultragenyx’s global margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Group Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups, though not direct buyers, strongly shape payer and regulator priorities; Ultragenyx saw this with the 2024 rare-disease campaigns that helped secure coverage for Burosumab-like agents, influencing formularies across 30+ US plans.\u003c\/p\u003e\n\u003cp\u003eTheir mobilization can push for lower prices or expanded access, pressuring Ultragenyx revenue—company FY2024 net product sales were $1.05B, so even small pricing concessions matter.\u003c\/p\u003e\n\u003cp\u003eTheir backing boosts uptake, but affordability demands can reduce realized price and extend reimbursement negotiations, delaying cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy steers payer focus; affected 30+ plans in 2024\u003c\/li\u003e\n\u003cli\u003eFY2024 net product sales $1.05B; pricing cuts hit revenue\u003c\/li\u003e\n\u003cli\u003eSupport increases uptake; demands prolong negotiations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative Tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn many countries, government drug tenders drive procurement; if multiple treatments or generics exist, agencies gain leverage and push prices down, forcing Ultragenyx to bid more competitively for multi-year supply deals.\u003c\/p\u003e\n\u003cp\u003eFor example, in 2024 WHO prequalification and EU national tenders awarded rare-disease drug contracts with price discounts often 20–35%, showing how alternatives squeeze maker margins and contract terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovernment tenders common globally\u003c\/li\u003e\n\u003cli\u003eMultiple treatments\/generics raise buyer power\u003c\/li\u003e\n\u003cli\u003e2024 tender discounts: ~20–35%\u003c\/li\u003e\n\u003cli\u003eUltragenyx may face tighter pricing and contract risks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers squeeze Ultragenyx: hefty rebates, PBM dominance, $1.05B sales hit net prices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (insurers, PBMs, govt payers) hold high leverage vs Ultragenyx: 2024 Medicaid rebates ~23.1%, PBM specialty rebates ~40%, top-three PBMs control ~60% of specialty scripts, FY2024 net sales $1.05B; EU\/WHO tender discounts 20–35% push net prices down, advocacy lifts access but can prolong reimbursement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid rebates\u003c\/td\u003e\n\u003ctd\u003e23.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM rebates\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑3 PBM share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 net sales\u003c\/td\u003e\n\u003ctd\u003e$1.05B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTender discounts\u003c\/td\u003e\n\u003ctd\u003e20–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eUltragenyx  Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Ultragenyx Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders or mockups—fully formatted and ready to download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746900750713,"sku":"ultragenyx-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ultragenyx-five-forces-analysis.png?v=1772193028","url":"https:\/\/matrixbcg.com\/products\/ultragenyx-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}